Evidence map›Paper›PMID 42403956›Full record

ArticleOncology letters2026

FBXL5 depletion as a novel strategy against osteosarcoma: Evidence for MEK/ERK inhibition and enhanced therapeutic sensitivity.

Yan-Chao Ma, Wen-Ming Zhou, Yong-Qiang Shi, Yan-Bo Dong, Hai-Hong Zhang, Wei Nan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yan-Chao MaDepartment of Orthopedics, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Wen-Ming ZhouDepartment of Orthopedics, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Yong-Qiang ShiDepartment of Orthopedics, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Yan-Bo DongDepartment of Orthopedics, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Hai-Hong ZhangDepartment of Orthopedics, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Wei NanDepartment of Orthopedics, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu 730000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor in adolescents. Despite standard treatments, including surgery and chemotherapy, the 5-year survival rate for metastatic OS remains <20%, underscoring the need for novel therapeutic targets. F-box and leucine-rich repeat protein 5 (FBXL5) is an E3 ubiquitin ligase that regulates iron homeostasis and exhibits complex functions across different tumors; however, its role in OS is still unclear. The present study employed the MG63 and 143B OS cell lines to investigate the oncogenic potential of FBXL5 through

Indexed as

apoptosisE3 ubiquitin ligaseF-box and leucine-rich repeat protein 5mitogen-activated protein kinase kinase/ extracellular signal-regulated kinase signaling pathwayosteosarcoma

Identifiers

PMID42403956
PMCPMC13329316

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.